Skip to main content

GOLDMAN SACHS GROUP INC

Position in PCVX — Vaxcyte, Inc.

CIK 886982 NEW YORK, NY

Position in PCVX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$78,519,677
+$4,427,337 QoQ
Shares Held
1,350,760
+5.9% QoQ
Ownership
0.908%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#23
of 329 holders
Holding Since
Jun 2020
24 quarters on record
Voting authority Sole 99% Shared 0% None 1%

Common Shares in PCVX Over Time

Shares Held

Position Value (USD)

Derivatives in PCVX

reported options exposure · as of Jun 30, 2026
CallValue
$1,459,063
CallShares
25,100
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

GOLDMAN SACHS GROUP INC holds $13,040,376,854 across 359 Biotechnology names. PCVX ranks #44 (0.6% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in PCVX

Export CSV
30 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,459,063 25,100
2026-06-30 $78,519,677 1,350,760
2026-03-31 $74,092,340 1,275,036
2026-03-31 $1,458,561 25,100
2025-12-31 $1,158,114 25,100
2025-12-31 $49,744,456 1,078,120
2025-09-30 $35,133,079 975,377
2025-06-30 $682,710 21,000
2025-06-30 $30,386,055 934,668
2025-03-31 $43,322,123 1,147,302
2025-03-31 $792,960 21,000
2025-03-31 $792,960 21,000
2024-12-31 $256,189,382 3,129,604
2024-09-30 $108,470,910 949,251
2024-06-30 $55,631,159 736,739
2024-03-31 $47,713,988 698,492
2023-12-31 $30,214,271 481,119
2023-09-30 $21,876,230 429,114
2023-06-30 $22,265,499 445,845
2023-03-31 $18,678,195 498,351
2022-12-31 $19,149,503 399,364
2022-09-30 $11,709,192 487,883
2022-06-30 $7,689,569 353,381
2022-03-31 $8,272,606 342,551
2021-12-31 $4,721,767 198,477
2021-09-30 $6,248,478 246,294
2021-06-30 $4,177,517 185,585
2021-03-31 $3,576,725 181,100
2020-12-31 $7,862,274 295,908
2020-06-30 $2,763,472 87,424